R&D grant and tax rebate are very different. At current stage PRR cannot enjoy the 45% tax rebate simply because it has not generated positive EBIT yet, no tax paid = no rebate. But once the product goes commercialized, it will reduce the company’s tax significantly.
This will not benefit shareholders in the tax perspective, but you can calculate it as a discount of SP in the long run if you buy it today.
Note the accounting treatment for R (research) and D (development) are very different.
And yes, this increases the possibility of PRR become a takeover target by those biotech giants in earlier stage in order to save their income tax and improve cash flow.
- Forums
- ASX - By Stock
- IMM
- interesting article from mergermarket
interesting article from mergermarket, page-8
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M |
Open | High | Low | Value | Volume |
32.0¢ | 32.0¢ | 31.5¢ | $547.1K | 1.721M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 72820 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 49499 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 56948 | 0.315 |
10 | 318753 | 0.310 |
16 | 278502 | 0.305 |
24 | 488907 | 0.300 |
5 | 113050 | 0.295 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 44490 | 2 |
0.330 | 60475 | 2 |
0.335 | 66276 | 3 |
0.340 | 103046 | 4 |
0.345 | 131753 | 5 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |